Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1192131078
rs1192131078
0.010 GeneticVariation BEFREE Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (<i>KLK3</i>) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (<i>P</i> = 2.3 × 10<sup>-8</sup>). 30538125

2019

dbSNP: rs369223448
rs369223448
0.010 GeneticVariation BEFREE Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation. 27509056

2016

dbSNP: rs781327047
rs781327047
0.010 GeneticVariation BEFREE Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation. 27509056

2016

dbSNP: rs141576693
rs141576693
0.010 GeneticVariation BEFREE Based on these results, we concluded that the p21 C70T polymorphism is associated with decreased risk of prostate cancer in Slovak men. 23292332

2013

dbSNP: rs538660698
rs538660698
0.010 GeneticVariation BEFREE Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. 20735386

2011

dbSNP: rs62113212
rs62113212
0.010 GeneticVariation BEFREE We did not observe a strong association with the KLK3 variant, reported in previous studies to confer risk for prostate cancer (rs2735839; P = 0.20) but did observe three highly correlated SNPs (rs17632542, rs62113212 and rs62113214) associated with prostate cancer [P = 3.41 × 10(-4), per-allele trend odds ratio (OR) = 0.77, 95% CI = 0.67-0.89]. 21318478

2011

dbSNP: rs62113214
rs62113214
0.010 GeneticVariation BEFREE We did not observe a strong association with the KLK3 variant, reported in previous studies to confer risk for prostate cancer (rs2735839; P = 0.20) but did observe three highly correlated SNPs (rs17632542, rs62113212 and rs62113214) associated with prostate cancer [P = 3.41 × 10(-4), per-allele trend odds ratio (OR) = 0.77, 95% CI = 0.67-0.89]. 21318478

2011

dbSNP: rs765521022
rs765521022
0.010 GeneticVariation BEFREE A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated. 15474988

2005

dbSNP: rs1450063773
rs1450063773
0.010 GeneticVariation BEFREE Three prostate cancer-derived p53 mutants (F134L, M237L, R273H) were introduced into LNCaP prostate cancer cells and stable transfectants established. 14587098

2003

dbSNP: rs61752561
rs61752561
0.020 GeneticVariation BEFREE The rs61752561 SNP appears to have a potential role in PCa pathogenesis by changing the glycosylation, protein stability, and PSA activity and may also affect the clinically measured F/T PSA ratio. 30538125

2019

dbSNP: rs61752561
rs61752561
0.020 GeneticVariation BEFREE The rs61752561 in KLK3 and rs2735839 in the KLK2-KLK3 intergenic region were strongly associated with prostate cancer-specific survival, and rs10486567 in the 7JAZF1 gene were associated with biochemical recurrence. 20460480

2010

dbSNP: rs746367915
rs746367915
0.020 GeneticVariation BEFREE An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed. 21178268

2010

dbSNP: rs746367915
rs746367915
0.020 GeneticVariation BEFREE This exploratory analysis in prostate cancer patients revealed the W allele of the KLK2 R250W SNP to be less likely associated with low GS morphology. 21178268

2010

dbSNP: rs746367915
rs746367915
0.020 GeneticVariation BEFREE Our results suggest that the C allele of the functional C748T polymorphism of KLK2 may increase the risk of PCa. 15643194

2005

dbSNP: rs149709822
rs149709822
0.040 GeneticVariation BEFREE This study tested the interactions of VDR (CDX2, FokI) and SRD5A2 (V89L, A49T) polymorphisms, and their associations with prostate cancer. 18483391

2008

dbSNP: rs149709822
rs149709822
0.040 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002

dbSNP: rs149709822
rs149709822
0.040 GeneticVariation BEFREE The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk. 12042668

2002

dbSNP: rs149709822
rs149709822
0.040 GeneticVariation BEFREE Our results suggest that the A49T mutation may influence the pathological characteristics of prostate cancers and, thus, may affect the prognosis of these patients. 10749132

2000

dbSNP: rs266882
rs266882
0.050 GeneticVariation BEFREE In addition, no association was observed between polymorphism A>G of rs266882 and risk of PCa. 30413614

2018

dbSNP: rs266882
rs266882
0.050 GeneticVariation BEFREE We evaluated the impact of genetic variation in the prostate-specific antigen (PSA) gene (rs266882) on serum PSA levels in healthy men as well as risk factors for benign prostate hypertrophy (BPH) and prostate cancer. 23315126

2013

dbSNP: rs266882
rs266882
0.050 GeneticVariation BEFREE Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features. 23235975

2012

dbSNP: rs266882
rs266882
0.050 GeneticVariation BEFREE Meta-analysis of 12 studies of rs266882 and overall p</span>rostate cancer risk was null. 18827812

2008

dbSNP: rs266882
rs266882
0.050 GeneticVariation BEFREE Men homozygous or heterozygous for the G/G (rs925013/rs266882) haplotype were at higher risk of prostate cancer than men homozygous for the A/A haplotype (odds ratio, 1.3; 95% CI, 1.1-1.7; P = 0.009). 16775173

2006

dbSNP: rs1058205
rs1058205
0.720 GeneticVariation BEFREE The overall results indicated that polymorphism T>C of rs1058</span>205 was associated with decreased risk of PCa</span> (allele contrast: OR = 0.75, 95% CI = 0.64-0.88, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.42-0.81, <i>P</i><sub>heterogeneity</sub> < 0.001), particularly in Caucasian population (allele contrast: OR = 0.77, 95% CI = 0.65-0.91, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.41-0.82, <i>P</i><sub>heterogeneity</sub> < 0.001). 30413614

2018

dbSNP: rs1058205
rs1058205
0.720 GeneticVariation BEFREE The frequency of the TC genotype of rs1058205 in the PCa group was significantly lower than that in the control group (P = 0.049). 28272245

2017